DOES ORAL CACO3 AND CALCITRIOL ADMINISTRATION FOR SECONDARY HYPERPARATHYROIDISM TREATMENT AFFECT THE LIPID PROFILE IN HD PATIENTS

Seventeen patients, 11 males and 6 females, ages 39 +/- 5.37 years (ra nge 16-63 years), with end-stage renal disease (ESRD) who had been mai ntained on hemodialysis (HD) for a mean period of 10.4 +/- 3.02 months were evaluated for the effects of oral CaCO3 and calcitriol on their lipid profile. All patients received a 40-g protein diet. None of the patients had a weight change or body mass index change (according to t he Du Bois calculating table) at the end of the study. During the firs t 3 months of the study, all subjects were given aluminum-containing p hosphate binders (2-3 g/day). Serum HDL, LDL, and total cholesterol, t riglyceride, calcium, phosphorus, and alkaline phosphatase levels weve measured both at the beginning and at the end of the 3-month period. These measurements were repeated 3 months later following CaCO3 (3 g/d ay) and calcitriol (0.25 mu g/day> therapy. While serum HDL, LDL, and total cholesterol and triglyceride levels were not changed after the a dministration of aluminum-containing phosphate binders, serum lipid st atus did improve following the CaCO3 and calcitriol therapy In conclus ion, three months of CaCO3 and calcitriol therapy reduced serum total cholesterol and LDL levels, and LDL/HDL ratios, and this therapy may i mprove the serum lipid profile to a point similar to the patient with lipid abnormalities but without renal disease.